U.S. Logistics Stock News

Boone Capital Management has disclosed a significant new position in Tyra Biosciences. The investment comes as Tyra Biosciences advances multiple clinical trials centered on FGFR3 biology. The move highlights fresh institutional interest in NasdaqGS:TYRA at a current share price of $37.15. For readers tracking Tyra Biosciences, the company now sits at a share price of $37.15 with substantial recent share price momentum, including a 26.4% return over the past 30 days and 38.7% year to date...

Intellicheck (IDN) has rounded out FY 2025 with fourth quarter revenue of about US$6.6 million and basic EPS of roughly US$0.08, alongside trailing twelve month revenue of US$22.7 million and EPS of about US$0.07 that reflect a move into positive net income of around US$1.3 million over the year. The company has seen quarterly revenue progress from US$4.9 million in Q1 2025 to US$6.6 million in Q4 2025, with EPS shifting from a small loss of roughly US$0.02 per share early in the year to a...

If you are wondering whether GPGI is attractively priced or already reflecting a lot of optimism, the current share price at US$17.06 raises some useful questions about what you are really paying for. Recent returns are mixed, with the stock up 3.3% over the last week but showing a 27.4% decline over 30 days, an 8.6% decline year to date, and gains of 51.0% over 1 year, 191.8% over 3 years, and 114.8% over 5 years. These moves sit against a backdrop of ongoing coverage that keeps GPGI on...

FDA grants premarket approval to LivaNova's aura6000 System for adult patients with moderate to severe Obstructive Sleep Apnea who do not benefit from standard therapies. The system uses proximal hypoglossal nerve stimulation and is supported by clinical trial data showing meaningful outcomes, including in harder to treat patient groups. LivaNova (NasdaqGS:LIVN) also discloses work on a next generation, MRI compatible version of the aura6000 with additional features. LivaNova, listed on...

Entergy highlighted its support for workforce development and community resilience at the Dress for Success New Orleans event. Company leaders and employees participated in the event, underscoring involvement in local career readiness efforts. For investors watching Entergy (NYSE:ETR), this kind of community engagement sits alongside a share price of $99.9 and a value score of 3. The stock has seen a 6.4% return year to date and a 22.4% return over the past year, which gives added context...

Axcelis Technologies (NasdaqGS: ACLS) will serve as the Diamond Sponsor of the Compound Semiconductor Asia Conference (CS Asia) 2026 during SEMICON China. The company plans to launch its next generation Purion Power Series+ Platform for chipmakers in China at the event. Axcelis CEO Mary Puma is scheduled to deliver a keynote address to industry participants and customers. Axcelis Technologies focuses on ion implantation and related processing equipment for the semiconductor sector, with...

Global Ship Lease (NYSE:GSL) files a new US$229 million Shelf Registration. The company also publishes its 2025 Annual Report, covering recent fleet acquisitions and charter activity. Both filings offer fresh detail on capital plans, fleet growth, and charter coverage for the year ahead. Global Ship Lease focuses on owning and chartering containerships, so its funding plans and fleet moves matter directly for earnings power and balance sheet risk. The new US$229 million Shelf Registration...

Belpointe PREP (OZ) just reported its FY 2025 numbers with Q4 total revenue of about US$3.1 million and a basic EPS loss of US$2.96, set against a trailing twelve month loss of US$10.17 per share on revenue of roughly US$9.2 million. Over the last six quarters, total revenue has moved from about US$0.86 million in Q3 2024 to US$3.06 million in Q4 2025, while quarterly basic EPS has ranged from a loss of US$1.85 per share to a loss of US$3.12. This leaves investors focused on how much of that...

Wondering whether Marqeta at around US$4.08 is a bargain or a value trap right now? This article breaks down what the current price actually reflects. The stock has moved 2.8% over the past week, is flat over 30 days, and is showing a 12.1% decline year to date with a 7.7% decline over the last year but a 14.3% gain across three years. This gives mixed signals about how the market is treating the story. Recent company updates and product announcements in the payments space have kept Marqeta...

Alumis (ALMS) has just wrapped up FY 2025 with Q4 revenue of US$1.9 million, a basic EPS loss of US$0.89 per share, and a net loss of US$92.9 million. On a trailing twelve month basis, revenue was US$24.1 million, with a basic EPS loss of US$2.86 per share and a net loss of US$243.3 million. Over recent quarters, revenue moved from US$17.4 million in Q1 2025 to US$2.7 million in Q2, US$2.1 million in Q3, and US$1.9 million in Q4. EPS shifted from a loss of US$1.82 in Q1 to a profit of US$0.78...

Fortune Brands Innovations (NYSE:FBIN) has appointed an interim CEO and an interim CFO while launching a formal search for a permanent chief executive. The company reached a governance cooperation agreement with activist investor Ed Garden, who has joined the board of directors. The board plans to phase out its classified structure, following internal leadership changes and shareholder pressure that appear aimed at avoiding a proxy fight. For investors watching NYSE:FBIN, these leadership...

Gold Royalty (NYSEAM:GROY) recently reported three consecutive quarters of positive free cash flow, which management has described as a financial inflection point. The company reported record annual revenue and cash flow, alongside a shift to a zero-debt capital structure after equitizing debt and completing a major equity raise. Gold Royalty expanded its portfolio with a new royalty on BHP's Pedra Branca mine, adding exposure to an operating asset. Gold Royalty, which last closed at $3.15,...

Ormat Technologies (NYSE:ORA) has priced $875 million of convertible senior notes in a significantly upsized offering. The company plans to use the proceeds to repurchase existing debt and shares, reshaping its capital structure. The transaction introduces new convertible securities that can affect future dilution and interest costs for shareholders. For readers tracking NYSE:ORA, this financing move comes with the stock at $110.52 and a 1 year return of 54.2%. Over 3 and 5 years, returns...

Edwards Lifesciences (NYSE:EW) has appointed Niranjan Pai as Director, Government Affairs. The new appointment places an experienced policy professional in a role focused on public policy and regulatory engagement. For investors tracking Edwards Lifesciences at a share price of $82.46, this move adds another piece to the broader picture around NYSE:EW. The company’s 1 year return of 16.2% sits alongside more modest 3 year and 5 year returns of 3.7% and 2.4%, which may prompt readers to pay...

Village Farms International reported fourth-quarter 2025 sales of US$49.62 million and net income of US$2.43 million, alongside full-year 2025 sales of US$215.94 million and net income of US$32.44 million, marking a shift from losses a year earlier. Over the same period, the company completed a repurchase of 812,923 shares for US$2.98 million, which, combined with the earnings turnaround, highlights management’s emphasis on improving profitability while also returning capital to...

ESAB Corporation (NYSE:ESAB) has priced a US$1b senior notes offering to fund the acquisition of Eddyfi Holding Inc. The deal is structured as a debt financed transaction, with the notes backed by guarantees from ESAB subsidiaries. This move follows a period of slower organic sales growth and reflects management’s focus on acquisitions to support expansion. ESAB, known for welding, cutting and gas control equipment, is moving to add Eddyfi’s testing and inspection capabilities to its...

Event context and recent share performance TEGNA (TGNA) shares recently closed at US$20.03, with the stock showing a roughly 1.3% decline over the past day, a 0.9% decline over the past week, and a 4.1% decline over the past month. See our latest analysis for TEGNA. While the recent 1 month share price return of a 4.1% decline has cooled momentum, the 1 year total shareholder return of 9.5% and 3 year total shareholder return of 39.5% point to a stronger longer term record. If you are...

CytomX Therapeutics recently reported full-year 2025 results showing sales of US$76.2 million and a net loss of US$17.37 million, and has just raised roughly US$250.00 million through a follow-on offering of common stock and pre-funded warrants at about US$5.30 per security. At the same time, the company released encouraging Phase 1 data for its EpCAM-targeted ADC Varseta-M in heavily pretreated metastatic colorectal cancer, with a high disease control rate and a safety profile that appears...

Titan America (NYSE:TTAM) has agreed to acquire Keystone Cement, expanding its presence and capacity in the Mid-Atlantic region. The company reports record revenue, EBITDA and operating cash flows for 2025, despite sector headwinds. These developments have not yet been widely discussed and may reshape Titan America's growth profile and operational footprint. For investors tracking NYSE:TTAM, the stock last closed at $14.71, with a 1 year return of 15.1% and a 12.0% decline year to date...

Why Protalix BioTherapeutics is Back on Investors’ Radar Protalix BioTherapeutics (PLX) has drawn fresh attention after the European Commission approved a new Elfabrio dosing regimen for certain Fabry disease patients, alongside updated 2026 revenue guidance that includes a US$25 million regulatory milestone. See our latest analysis for Protalix BioTherapeutics. The Elfabrio dosing news and 2026 guidance update arrive after a mixed share price pattern, with a 28.9% 90 day share price return...

Ovid Therapeutics (OVID) has drawn fresh attention after reporting Phase 1 data for its OV329 epilepsy program at a 7 mg dose, alongside plans to expand into new seizure indications backed by about US$60 million in private financing. See our latest analysis for Ovid Therapeutics. The new OV329 data and US$60 million financing arrive after a sharp run in the stock, with a 30 day share price return of 60.84% and a 1 year total shareholder return above 400%, even though the 3 year and 5 year...

Collegium Pharmaceutical (NasdaqGS:COLL) has entered into a definitive agreement to acquire AZSTARYS. The deal expands Collegium’s ADHD portfolio and secures longer-term product exclusivity for its ADHD offerings. The transaction is described as immediately accretive to adjusted EBITDA. For investors following the ADHD treatment space, this move provides another data point on how branded therapies are being repositioned. Collegium, which focuses on pain and ADHD treatments, is adding...

Globant (NYSE:GLOB) announced an AI focused collaboration with PharmaMar to support cancer drug discovery efforts. The company also agreed a global integration partnership with payments platform Adyen for enterprise clients. Both arrangements position Globant in healthcare and fintech projects tied to drug research and digital payments infrastructure. Globant operates as a digital services and technology company, working with enterprises that are investing in cloud, data and AI based...

CONMED (NYSE:CNMD) has exited the gastroenterology market and transferred global distribution rights for certain product lines to Micro-Tech Endoscopy. The company has also appointed Andrew Moller as Interim Chief Financial Officer. For investors watching NYSE:CNMD, these moves come at a time when the share price is around $36.8 and multi year returns have been weak, with the stock down 37.1% over 1 year, 60.8% over 3 years, and 69.5% over 5 years. Stepping away from gastroenterology...